News

Exploring Chevron's Options Activity and Market Position

Exploring Chevron's Options Activity and Market Position

Understanding Recent Options Activity at Chevron

Investors with significant resources have adopted a bullish stance on Chevron (CVX), an indicator that market participants should pay attention to. Recent analytic efforts to track public options have uncovered noteworthy movements today, highlighting a trend that often precedes notable market shifts.

Our observations today revealed a sharp spike in options trading activities related to Chevron. The volume and type of these trades are particularly telling, suggesting there may be something significant on the horizon.

Analyzing Market Sentiment

The sentiment among major investors appears to be mixed, with approximately 50% of the trades reflecting bullish expectations while about 37% indicate a bearish outlook. Among the prominent options tracked, there were two puts worth $120,230, contrasted by six calls totaling $229,971.

Projecting Price Movements

Current trading behaviors hint that these key investors are targeting Chevron's price to range between $130.00 and $155.00 within the next three months. Such ranges often provide insight into potential market movements.

Volume and Open Interest Trends

Focusing on trading activity, Chevron's options today show an average open interest of approximately 1478.57 and a total volume of 1,475.00. This data reveals a solid interest in Chevron’s options amid fluctuating market dynamics.

Options Overview for Chevron

In examining Chevron's options landscape over the past month, traders are particularly invested in the strike prices between $130.00 and $155.00. The behavior of these trades indicates a significant level of market engagement.

Highlighting Key Options Trades

Reviewing the options data provides clear insights into active trades:

  • Put Option: $3.3 at a $149.00 strike for expiration on January 17, 2025 with significant volume.
  • Call Option: $6.15 at a $145.00 strike for expiration on February 21, 2025, indicating bullish sentiment.
  • Call Option: $2.47 at a $155.00 strike due for March 21, 2025 suggests careful positioning.
  • Put Option: $7.4 at a $150.00 strike for March 21, 2025, reflecting a divided investor sentiment.
  • Call Option: Trade at $2.2 for $146.00 strike due on January 10, 2025, showing keen interest.

Company Overview: Chevron

Chevron is a leading integrated energy company active in exploration, production, and refining on a global scale. As the second-largest oil firm in the United States, Chevron produces approximately 3.1 million barrels of oil equivalent daily, which includes a substantial amount of natural gas and liquids. The company operates in various regions around the world, from North America to Asia, showcasing its expansive operational capacity.

Chevron's refining capabilities across the United States and Asia underline its commitment to maintaining a robust supply chain, with a total refining capacity amounting to 1.8 million barrels of oil per day. Proven reserves at the end of the previous year owned by Chevron are also noteworthy, with estimates at 11.1 billion barrels of oil equivalent, emphasizing the company's solid position in the energy market.

Recent Stock Performance

Currently, Chevron is showing a trading volume of 1,353,849, with its stock price standing at $147.44, reflecting a 1.8% increase. Important technical indicators like the RSI are suggesting the stock may be reaching oversold conditions, warranting attention from investors.

Insights from Financial Analysts

Several expert analysts have weighed in on Chevron’s stock performance recently, providing an optimistic average price target of around $173.67. Notable analysts including those from Piper Sandler and Wells Fargo have set price targets of $173 and $188, respectively, reflecting continued confidence in Chevron's prospects.

Opportunities for Investors

While trading options inherently involves risks, they also present substantial potential for negotiating profits. Investors can mitigate risks by focusing on education, engaging in strategic trading modifications, and monitoring market trends closely. Real-time alerts regarding Chevron's options trading can help savvy traders capitalize on emerging opportunities.

Frequently Asked Questions

What is Chevron's stock ticker symbol?

Chevron's stock ticker symbol is CVX, traded on the NYSE.

What recent options activity has been reported for Chevron?

Recent activity shows increased interest from large investors, with mixed sentiment across various call and put options.

What are the expected price ranges for Chevron stock?

Key investors are predicting Chevron's stock to range between $130.00 and $155.00 in the coming months.

Who tracks Chevron's options activity?

Various financial analysts and scanners monitor Chevron's options, providing insights into market trends.

What do analysts think about Chevron's stock?

Financial analysts generally maintain a positive outlook on Chevron, with targets mostly above $170.00.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading